Reach Us +1-217-403-9671
Targeting Cancer Stem Cells: Challenges And Opportunities | 8212
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Targeting cancer stem cells: Challenges and opportunities

2nd World Congress on Bioavailability & Bioequivalence: Pharmaceutical R & D Summit-2011 and International Conference on Pharmaceutics & Novel Drug Delivery Systems

Xiaoyan Jiang

ScientificTracks Abstracts: JBB

DOI: 10.4172/2153-2435.10000S4

Given the current uncertain climate of pharmaceutical industry, with FDA approved NCEs continue to stagger, antibacterial discovery faces unprecedented challenges, however, huge opportunities exist because the well recognized medical need for new agents to fi ght MDR bacterial infections, such as conditions caused by MRSA and VRE, and also a strong industrial appeal for incentives to invest in this area with orphan drug status, for instance, be granted to novel therapeutics. Here we use one AstraZeneca discovery program to illustrate the challenges and opportunities. Th e inhibition of essential cell-wall targets, such as Glutamate Racemase (MurI), provides a great opportunity to design the next generation of antibacterials. Th is talk will be focused on the recent eff orts of discovering MurI inhibitors in Gram-positive bacteria and Gram-negative Helicobacter Pylori. Th e entire discovery process from High Th roughput Screening, Lead Identifi cation and Lead Optimization will be presented. Emphasis will be given to the demonstration of the power of HTS to discover allosteric enzyme inhibitors and Structural Activity Relationship development employing Structure-Based Drug Design approach.
Dr. Xiaoyan Jiang is a Senior Scientist in the Terry Fox Laboratory of the BC Cancer Agency, an Associate Professor in the Department of Medical Genetics and an Associate Member in the Department of Medicine at the University of British Columbia. She is also an Adjunct Professor at the Shanghai Institute of Medical Genetics of the Shanghai Jiao Tong University. She serves as an Editorial Board Member of 10 reputed journals, an external (ad hoc) reviewer for more than 20 journals and a research grant reviewer in Canada and the USA. She has published 45 peers-reviewed publications and 75 Abstracts.